Key facts
- AUM Biosciences’s last known valuation is $98.7M (Oct 2021).
- It has raised $29.7M; the latest was Later Stage VC in Feb 2026.
- Notable investors include SPRIM Global Investments, ASA Capital Partners, Accelerate Technologies, Agency for Science, Anexa Capital (US) — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for AUM Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for AUM Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AUM Biosciences
Developer of an oncology-focused biotechnology platform designed to help in harnessing the power of digital and precision medicine. The company utilizes a proprietary partnered AI-augmented platform to systematically discover and develop targeted cancer therapies focused on genetic targets, enabling patients to access the right medicines at the right time.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2018
- Employees
- 19
- Website
- aumbiosciences.com/
- Ownership
- Privately Held (backing)
AUM Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AUM Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AUM Biosciences in its N-PORT filings yet. We sweep new filings monthly.